A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum

Trial Profile

A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Pyoderma gangrenosum
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2015 New trial record
    • 16 Oct 2015 Results published in British Journal of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top